BioNTech SE BNTX shares are trading higher Monday after the company reported financial results and reaffirmed its 2022 outlook.
BioNTech reported first-quarter revenue of 6.37 billion euros ($6.72 billion), which was up from €2.05 billion year-over-year. The company reported quarterly earnings of €14.24 per share, up from earnings of €4.39 per share, year-over-year.
"As a result of an increased order volume initially placed in late 2021 following the then emerging Omicron variant, we began the year 2022 with strong revenues and earnings, leaving us well-positioned to achieve the 2022 financial guidance we issued a few months ago," said Jens Holstein, CFO of BioNTech.
BioNTech reiterated its previously issued 2022 expectations, which includes €13 billion to €17 billion in estimated COVID-19 vaccines revenues.
See Also: Why Palantir Technologies Shares Are Diving
BNTX 52-Week Range: $121.32 - $464
The stock was up 4.95% at $142.91 at time of publication.
Photo: courtesy of BioNTech.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.